Cancer Institute A national cancer institute
designated cancer center
noThumbs = true, sDelay = 8000

Stanford Hematology Program

Developing novel therapies for leukemia and blood diseases

Stanford Hematology Program

Leaders in research for all types of leukemia

Stanford Hematology Program

Recognized specialists in hematologic disorders

Stanford Hematology Program

Working with many rare forms of blood disorders, the Stanford Hematology Program brings together a multidisciplinary team of experts dedicated to treating leukemia as well as other benign and malignant hematologic disorders. Features of the program include:

  • State-of-the-art chemotherapy treatments
  • Doctors who specialize exclusively in benign and malignant hematologic disorders
  • Clinical trials using targeted therapies and novel agents

Benefits to you

Comprehensive care for optimal outcomes. Doctors in the Hematology Program regularly collaborate with specialists in the Blood and Marrow Transplant program and other disciplines, including infectious diseases, radiation oncology, and interventional radiology.

Innovative research in clinical trials. Stanford has an extensive portfolio of clinical trials using novel therapies and investigational agents for all types of leukemia, multiple myeloma, and myelopfoliferative neoplasms.

Childhood Leukemia

Leukemia is the most common form of cancer in childhood. It affects approximately 3,000 children each year in the United States, accounting for about 30% of childhood cancers. Information about childhood leukemia can be found at the Stanford Children’s Health, which is within easy walking distance from both the Stanford Cancer Center and Stanford Hospital & Clinics.

 

Stanford Medicine Resources:

Footer Links: